Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer

European Journal of Surgical Oncology

Volumn 34, Issue 12, 2008, Pages 1299-1303

  Neri, A ^a   Marrelli, D ^a   Pedrazzani, C ^a   Caruso, S ^a   De Stefano, A ^a   Mariani, F ^a   Megha, T ^a   De Marco, G ^a   Corso, G ^a   Pinto, E ^a   Roviello, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Breast cancer; Mib 1; Multivariate analysis; Prognosis; Proliferation index; Prospective study

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 54849419962     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.11.009     Document Type: Article

References (28)

1. Goldhirsh A., Glick J.H., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
2. Mirza A.N., Mirza N.Q., Vlastos G., and Singletary E. Prognostic factors in node-negative breast cancer. Ann Surg 235 (2002) 10-26
3. Colozza M., Azambuja E., Cardoso F., Sotiriu C., Larsimont D., and Piccart M.J. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 16 (2005) 1723-1739
4. Liu S., Edgerton S.M., Moore D.H., and Thor A.D. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7 (2001) 1716-1723
5. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23 (2005) 7212-7220
6. Scholzen T., and Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182 (2000) 311-322
7. Clarke R.B., Howell A., Potten C.S., and Anderson E. Dissociation between steroid receptor expression and cell proliferation in human breast. Cancer Res 57 (1997) 4987-4991
8. Cattoretti G., Becker M.H., Key G., et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (Mib1 and Mib3 detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168 (1992) 357-363
9. Marrelli D., Pinto E., Neri A., et al. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer. A prospective study on 675 patients. Oncol Rep 15 (2006) 425-429
10. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133 (1984) 1710-1715
11. Offersen B.V., Sorensen F.B., Knoop A., and Overgard J. The prognostic relevance of proliferative activity in early breast cancer. Histopathology 43 (2003) 573-582
12. Gaglia P., Bernardi A., Venesio T., et al. Cell proliferation of breast cancer evaluated by antiBrdU and anti Ki-67 antibodies: its prognostic value on short term recurrences. Eur J Cancer 29A (1993) 1509-1513
13. Weikel W., Brumm C., Wilkens C., Beck T., and Knapstein P.G. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node negative tumors. Cancer Detect Prev 19 (1995) 446-450
14. Seshadri R., Leong A.S., McCaul K., Firgaira F.A., Setlur V., and Horsfall D.J. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 69 (1996) 135-141
15. Broen R.W., Allred C.D., Clark G.M., Osborne C.K., and Hilsenbek S.G. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2 (1996) 585-592
16. Haerslev T., Jacobsen G.K., and Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in breast cancer. Breast Cancer Res Treat 37 (1996) 101-113
17. Molino A., Micciolo R., Turazza M., et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74 (1997) 433-437
18. Iacopetta B., Grieu F., Powell B., Soong R., McCaul K., and Sashadri R. Analysis of p53 gene mutation by polymerase chain reaction - single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 4 (1998) 1597-1602
19. Thor A.D., Liu S., Moore D.H., and Edgerton S.M. Comparison of mitotic index, in vitro bromodeoxyuridine labelling and Mib-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17 (1999) 470-477
20. Clahsen P.C., van de Velde C.J., Duval C., et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 25 (1999) 356-363
21. Billgren A.M., Tani E., Liedberg A., Skoog L., and Rutqvist L.E. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat 71 (2002) 161-170
22. Trihia H., Murray S., Price K., et al. Ki-67 expression in breast cancer. Its association with grading systems, clinical parameters and other prognostic factors - a surrogate marker?. Cancer 97 (2003) 1321-1331
23. Joensuu H., Isola J., Lundin M., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9 (2003) 923-9330
24. Railo M., Luldin J., Haglund C., von Smitten K., and Nordling S. Ki-67, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol 28 (2007) 45-51
25. Spyratos F., Ferrero-Pous M., Tressard M., et al. Correlation between Mib-1 and other proliferation markers. Clinical implications of the Mib-1 cutoff value. Cancer 94 (2002) 2151-2159
26. Colleoni M., Rotzmens N., Peruzzotti G., et al. Minimal and small size invasive breast cancer with no axillary involvement: the need for tailored adjuvant therapies. Ann Oncol 15 (2004) 1633-1639
27. Soerjomataram I., Louwman W.J., Ribot J.G., Roukema J.A., and Coebergh W.E. An overview of prognostic factors for long term survivors of breast cancer. Breast Cancer Res Treat 22 (2007) [ePub ahead of print]
28. Hanrahan E.O., Valero V., Gonzales-Angulo A.M., and Hortobagy G.N. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; pT1a,bN0Mx): a review of the literature. J Clin Oncol 24 (2006) 2113-2122